RA Capital Management L.P. Lowers Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

RA Capital Management L.P. reduced its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 20.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 848,986 shares of the company's stock after selling 212,247 shares during the quarter. RA Capital Management L.P. owned about 1.74% of Enliven Therapeutics worth $19,102,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. Tower Research Capital LLC TRC boosted its position in shares of Enliven Therapeutics by 230.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock worth $36,000 after acquiring an additional 1,114 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Enliven Therapeutics during the 4th quarter valued at about $97,000. ExodusPoint Capital Management LP purchased a new position in shares of Enliven Therapeutics during the fourth quarter valued at about $200,000. China Universal Asset Management Co. Ltd. grew its position in shares of Enliven Therapeutics by 14.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company's stock valued at $233,000 after purchasing an additional 1,275 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of Enliven Therapeutics by 17.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,627 shares of the company's stock worth $307,000 after buying an additional 1,980 shares in the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Enliven Therapeutics

In related news, insider Joseph P. Lyssikatos sold 5,000 shares of Enliven Therapeutics stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $16.07, for a total transaction of $80,350.00. Following the completion of the transaction, the insider now directly owns 997,688 shares of the company's stock, valued at approximately $16,032,846.16. The trade was a 0.50 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Benjamin Hohl sold 3,250 shares of the stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $18.69, for a total transaction of $60,742.50. Following the completion of the sale, the chief financial officer now directly owns 23,000 shares in the company, valued at $429,870. This trade represents a 12.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 66,751 shares of company stock worth $1,331,288. 29.20% of the stock is currently owned by company insiders.

Enliven Therapeutics Stock Up 3.3 %

Enliven Therapeutics stock traded up $0.66 during mid-day trading on Friday, reaching $20.51. 221,177 shares of the company's stock traded hands, compared to its average volume of 259,995. Enliven Therapeutics, Inc. has a 12-month low of $13.30 and a 12-month high of $30.03. The stock has a 50 day moving average of $19.17 and a two-hundred day moving average of $22.38. The company has a market cap of $1.01 billion, a price-to-earnings ratio of -10.79 and a beta of 1.07.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings results on Thursday, March 13th. The company reported ($0.46) EPS for the quarter, beating analysts' consensus estimates of ($0.53) by $0.07. The business had revenue of $0.03 million during the quarter. As a group, sell-side analysts forecast that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright raised their price target on Enliven Therapeutics from $37.00 to $39.00 and gave the company a "buy" rating in a report on Friday, March 21st.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.